Key Developments: Cytomedix Inc (CMXI.PK)

CMXI.PK on OTC Markets Group

22 Aug 2014
Price Change (% chg)

$-0.02 (-5.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cytomedix completes the second tranche of the $35 mln convertible debt financing with Deerfield Management Company
Thursday, 26 Jun 2014 08:00am EDT 

Cytomedix Inc:Completes second tranche of the gross proceeds in the amount of $26 mln (for a total $35 million) in convertible debt financing from certain investment funds managed by Deerfield Management Company, L.P.Deerfield agreed to provide to the Company up to $35 mln in financing through a senior secured convertible debt facility. The commitment consisted of two separate tranches.Second tranche in the gross amount of $26 million was completed as anticipated.Net proceeds to the Company were about $22.1 mln.  Full Article

Cytomedix Inc announces convertible debt financing
Monday, 31 Mar 2014 04:30pm EDT 

Cytomedix Inc:Enters into convertible credit facility of up to $35 mln with certain investment funds managed by Deerfield Management Company, L.P.Says in addition $2 mln equity investment with Anson Group.  Full Article

Cytomedix Inc Announces CFO Change-Form 8-K
Wednesday, 3 Apr 2013 08:45am EDT 

Cytomedix Inc reported in its Form 8-K that on March 29, 2013, Andrew S. Maslan, the Chief Financial Officer (CFO) of Cytomedix, Inc. (Company), tendered his resignation as the Company’s CFO and Secretary effective as of May 10, 2013. On March 30, 2013, the Board appointed Mr. Steven S. Shallcross as the Company’s Executive Vice President, Chief Financial Officer (CFO), Secretary and Treasurer, commencing on as of May 10, 2013.  Full Article

Cytomedix Inc Announces Positive Results With Angel cPRP in Veterinary Application
Friday, 7 Dec 2012 08:00am EST 

Cytomedix Inc announced that positive data on the Angel(R) cPRP system in a veterinary application treatment of persistent mating induced endometritis (PMIE) in mares were recently presented at the 3rd annual conference of the North American Veterinary Regenerative Medicine Association (NAVRMA) in Savannah, GA. Treatment with PRP was shown to be associated with a statistically significant reduction in certain endometrial pro-inflammatory cytokines and inducible nitric oxide synthetase (iNOS), both known to be involved in the pathology of PMIE. Many mares fail to respond to conventional therapies and recent studies have shown a link between PMIE and the expression of certain cytokines. Nitric oxide is also believed to play a role in uterine clearance. The study investigated 9 barren mares with a history of PMIE. During the treatment cycle, whole blood was processed using the Angel cPRP system and the resultant PRP was brought to a final volume with platelet poor plasma and infused into the uterus. All mares were then inseminated with motile sperm. Evaluation of endometrial biopsies showed that in mares treated with PRP there was down-regulated expression of pro-inflammatory molecules, IL-1b, IL-6, IL-8 and iNOS, compared with untreated mares (p < 0.05).  Full Article

Search Stocks